%0 Journal Article
%T Halcyon<sup>TM</sup> Acuros XB vs AAA: A RapidArc Planning Comparison for Head & Neck Cancers
%A Jonathan Mbewe
%A Sakhele Shiba
%J International Journal of Medical Physics,Clinical Engineering and Radiation Oncology
%P 189-199
%@ 2168-5444
%D 2022
%I Scientific Research Publishing
%R 10.4236/ijmpcero.2022.114016
%X The Halcyon O-ring gantry
linear accelerator from Varian Medical Systems is delivered with a hardcoded</span><span style=\"font-size:10.0pt;font-family:&quot;\"> </span><span style=\"font-size:10.0pt;font-family:&quot;\">beam-source model and Analytical Anisotropic Algorithm dose calculation
algorithm</span><span style=\"font-size:10.0pt;font-family:&quot;\"> </span><span style=\"font-size:10.0pt;font-family:&quot;\">as standard, while the Acuros XB </span><span style=\"font-size:10.0pt;font-family:&quot;\">algorithm is a purchasable option. The models in both algorithms are
facto</span><span style=\"font-size:10.0pt;font-family:&quot;\">ry-configured and do not permit fine-tuning by
the user. In this study, we compared the two algorithms for sequential boost
RapidArc treatment planning of Head &amp; Neck cancers using D98%, D95%, D50%,
D2% and maximum dose</span><span style=\"font-size:10.0pt;font-family:&quot;\"> </span><span style=\"font-size:10.0pt;font-family:&quot;\">to assess dose coverage of</span><span style=\"font-size:10.0pt;font-family:&quot;\"> </span><span style=\"font-size:10.0pt;font-family:&quot;\">nodal and tumor planning target volumes (PTV_N
and PTV_T, respectively), and cochlear D5%, parotid D20%, D50%, mean dose, and
cord maximum dose to evaluate doses to organs-</span><span style=\"font-size:10.0pt;font-family:&quot;\"> </span><span style=\"font-size:10.0pt;font-family:&quot;\">at-risk. The conformity index (CI),
homogeneity index (HI) and total number of monitor units (MU) quantified plan
quality. We found statistically significant differences in PTV_N D2%, maximum
dose, HI, PTV_T D98%, D95%, D2%, Max, HI, and total MU. Statistically
significant differences in Cochlear D5% and Parotid mean doses were also
encountered. These differences may not necessarily be clinically significant,
however. Therefore, we believe that both calculation algorithms are adequate
for RapidArc planning of Head &amp; Neck can</span><span style=\"font-size:10.0pt;font-family:&quot;\">cers.
%K Halcyon
%K Acuros XB
%K AAA
%K RapidArc
%K Head and Neck
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=120164